OKUR - OnKure Therapeutics Inc Bozor kapitallashuvining balans qiymatiga nisbati

onkuretherapeutics.com (OKUR) korporativ emblemasi va logotipi

OnKure Therapeutics Inc (OKUR) biznes modeli PI3Kα ingibitorlarining muvaffaqiyatiga va qattiq o'smalar uchun kombinatsiyalangan terapiyaning xavfsizligiga tayanadi. Kompaniya saratonga qarshi agentlarni ishlab chiqargani sababli, uning o'sishi bozor sikllaridan mustaqil ravishda amalga oshiriladi va ushbu ko'rsatkich 0.62 darajasida turibdi. Quyida ko'rsatilgan narx trayektoriyasi aktivlar tahlilini to'ldiradi. Firma hozirda o'z patentlarini himoya qilish uchun o'smalarning qarshilik ko'rsatishini yengib, maqsadli terapiya sohasida yetakchilik uchun kurashmoqda.

OnKure Therapeutics (OKUR) - Bozor kapitallashuvining balans qiymatiga nisbati 08.10.2024dan 31.10.2026gacha

OnKure Therapeutics Inc (OKUR) kompaniyasining tahliliy kesimlari va maʼlumotlar hisoboti

- bozor qiymati va tahlilchilarning maqsadli prognozi:
Narx grafigi onkuretherapeutics.com|OKUR - Adolatli qiymat konsensusi
- bozor kapitallashuvi statistikasi:
Bozor kapitallashuvi OnKure|OKUR - Kompaniyani butunlay sotib olishdagi haqiqiy narx
- buxgalteriya balansi bo'yicha sof aktivlar qiymati ko'rsatkichlari:
Bitta aksiya hisobiga balans qiymati OnKure Therapeutics|OKUR - Balans kapitallashuvi|Bozor qiymatining balans qiymatiga nisbati onkuretherapeutics.com|OKUR - Biznesning umumiy aktivlari
- qarzdorlik va likvidlik to'g'risida ma'lumotlar:
Umumiy qarzning kapitalga nisbati OnKure Therapeutics Inc|OKUR - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzning kapitalga nisbati onkuretherapeutics.com|OKUR - Kompaniyaning umumiy yig'indi qarzi|Qarzning balans kapitallashuviga nisbati OnKure|OKUR - Kompaniyaning uzoq muddatli kredit va qarzlari|Kompaniyaning qisqa muddatli majburiyatlari OnKure Therapeutics|Tezkor likvidlik koeffitsiyenti onkuretherapeutics.com
- foyda va baholash multiplikatorlari ko'rsatkichlari:
OKUR - Sof daromad
Kompaniyaning har tomonlama tahlili:OnKure Therapeutics Inc
OnKure Therapeutics Inc yetakchi tovari

Molekulalar sintezini tashqi pudratchilarga topshiradigan OnKure Therapeutics Inc (OKUR) ning virtual modeli intellektual mulkni asosiy aktiv sifatida belgilaydi. Ushbu ko'rsatkich biznesning bozor qiymatini uning sof aktivlari bilan solishtirib, obyektiv kapital va investorlar kutganlari o'rtasidagi farqni ochib beradi. Bozor kapitalizatsiyasining buxgalteriya qiymatiga nisbati ko'rsatilgan ushbu grafikni tahlil qilish orqali kelajakdagi patentlar uchun to'langan premiumning miqdorini baholash mumkin. Ko'rsatkichning pasayishi aktivlar qiymatiga bo'lgan ishonchning pasayishidan dalolat beradi. Natijada, ushbu metrika kompaniyaning balans hisoboti ustidan joriy bozor premiumini belgilaydi.

OnKure Therapeutics Inc kimlar bilan raqobatlashadi

BeiGene Ltd (ONC) - Bozor qiymatining balans qiymatiga nisbati|halozyme.com - Balans qiymatiga nisbatan bozor qiymati|RVMD (Revolution Medicines, Inc.) - Bozor kapitallashuvining balans qiymatiga nisbati|Kapitallashuvning sof aktivlarga nisbati Ascentage Pharma Group International (AAPG)|Bozor kapitallashuvining balans qiymatiga nisbati CGON|Bozor kapitallashuvining balans qiymatiga nisbati UroGen Pharma Corp (URGN)|Bozor qiymatining balans qiymatiga nisbati Bicara Therapeutics Inc. BCAX|PSNL: Kapitallashuvning balans qiymatiga nisbati|Erasca - Bozor kapitallashuvining balans qiymatiga nisbati|Delcath Systems Inc (DCTH) - Kapitallashuvning sof aktivlarga nisbati|YMAB: Bozor kapitallashuvining balans qiymatiga nisbati|Bozor qiymatining balans qiymatiga koeffitsiyenti Aura Corp (AURA)|Bozor qiymatining balans qiymatiga nisbati Candel Therapeutics Inc.|ARAY: Balans qiymatiga nisbatan bozor qiymati|Kapitallashuvning sof aktivlarga nisbati SLS (SELLAS Life Sciences)|ACTU (Actuate Therapeutics Inc.) - Balans qiymatiga nisbatan bozor qiymati|Bozor kapitallashuvining balans qiymatiga nisbati CTOR (Citius Oncology, Inc)|HURA - Kapitallashuvning sof aktivlarga nisbati|TARA: Kapitallashuvning sof aktivlarga nisbati|FATE - Bozor kapitallashuvining balans qiymatiga nisbati|aadibio.com (WHWK) - Bozor qiymatining balans qiymatiga nisbati|TScan Therapeutics, Inc. - Balans qiymatiga nisbatan bozor qiymati|CSBR (Champions Oncology Inc) - Bozor kapitallashuvining balans qiymatiga nisbati|Bozor qiymatining balans qiymatiga koeffitsiyenti XBiotech USA XBIT|Bozor qiymatining balans qiymatiga nisbati CEL-SCI Corporation (CVM)|OSTX - Bozor qiymatining balans qiymatiga koeffitsiyenti|Bozor qiymatining balans qiymatiga nisbati Radiopharm Theranostics RADX|ARTV: Kapitallashuvning balans qiymatiga nisbati|ANL - Bozor qiymatining balans qiymatiga nisbati|VERU - Bozor kapitallashuvining balans qiymatiga nisbati|TPST (Tempest Therapeutics) - Kapitallashuvning sof aktivlarga nisbati|Xilio Therapeutics (XLO) - Bozor kapitallashuvining balans qiymatiga nisbati|Bozor qiymatining balans qiymatiga nisbati Renovaro Biosciences|MURA: Balans qiymatiga nisbatan bozor qiymati|Bozor kapitallashuvining balans qiymatiga nisbati KAPA|GDTC - Bozor qiymatining balans qiymatiga koeffitsiyenti|Curis - Kapitallashuvning sof aktivlarga nisbati|Balans qiymatiga nisbatan bozor qiymati APLM|THAR: Kapitallashuvning sof aktivlarga nisbati|Advanced Biomed Inc - Bozor kapitallashuvining balans qiymatiga multiplikatori|GNPX: Bozor kapitallashuvining balans qiymatiga nisbati|Calidi Biotherapeutics, Inc. - Balans qiymatiga nisbatan bozor qiymati|SBFM (Sunshine Biopharma) - Bozor kapitallashuvining balans qiymatiga nisbati|Bozor qiymatining balans qiymatiga koeffitsiyenti Xenetic Bio XBIO|Bozor qiymatining balans qiymatiga nisbati Salarius Pharmaceuticals, Inc. (SLRX)|PPBT (Purple Biotech Ltd) - Balans qiymatiga nisbatan bozor qiymati|Bozor kapitallashuvining balans qiymatiga nisbati AONC (American Oncology Network, Inc.)|Bozor kapitallashuvining balans qiymatiga nisbati BeiGene Ltd BGNE|CKPT - Bozor qiymatining balans qiymatiga nisbati|Sof aktivlarga nisbatan bozor kapitallashuvi ELEV|ICAD: Bozor kapitallashuvining balans qiymatiga nisbati|Bozor qiymatining balans qiymatiga koeffitsiyenti Ikena Oncology (IKNA)|Kapitallashuvning sof aktivlarga nisbati NTBL|Bozor kapitallashuvining balans qiymatiga nisbati Viracta|Kapitallashuvning sof aktivlarga nisbati MOR (MorphoSys AG)|Bozor kapitallashuvining balans qiymatiga multiplikatori NAYA|Bozor kapitallashuvining balans qiymatiga nisbati AAPGV (Ascentage Pharma)